



CHRYsalis CAPITAL IX ANNOUNCES CLOSING OF QUALIFYING TRANSACTION WITH INSPIRA FINANCIAL INC. AND ANTICIPATED DATE OF TRADING

Toronto, Ontario, July 8, 2015 – Chrysalis Capital IX Corporation (TSXV:NYN.P) (“**Chrysalis IX**”) is pleased to announce the closing of its previously announced Qualifying Transaction with Inspira Financial Inc. (“**Inspira**”). As a result of the transactions completed in connection with the Qualifying Transaction, Chrysalis IX is now a British Columbia corporation called “Inspira Financial Inc.” (the “**Resulting Issuer**”).

Inspira Financial Inc.

Inspira targets small healthcare providers throughout the United States by offering revolving lines of credit (“RLOC”) and loans ranging from \$250,000 to \$10 million and is able to generate yields of up to 20% annually, represented by a mixture of interest and fees. With access to low-cost credit markets and facilities, Inspira plans to leverage its RLOC and loan book up to 80% and continue adding clients through direct marketing and originator channel partnerships. Inspira’s management believes the current, fully-diluted capital structure with appropriate leverage can generate a \$500 million book, with a significant amount of free cash flow.

Despite the growth opportunities found in an aging population and rebounding economy, smaller healthcare providers in the United States face a challenging finance market; traditional banks continue to reduce their risk profiles, term lenders require personal guarantees and first security over all assets, factoring lenders charge significant annual interest and specialized medical equipment providers often do not offer financing programs. By targeting the hundreds of thousands of healthcare providers in the United States, Inspira plans to generate significant returns on its RLOC and loan book collateralized by government (Medicare/Medicaid) and large healthcare insurance accounts receivable.

As an additional growth strategy, Inspira will focus on rolling up the highly fragmented market of small companies in the fast growing market for alternative financial services offered to healthcare providers and their patients. Businesses such as medical bill collection agencies and medical equipment leasing companies offer services and products to alleviate working capital problems experienced by physician offices driven by cuts in reimbursement and increased patient financial responsibility of medical bills. Inspira plans to acquire these types of businesses and increase revenues through cross-selling a full range of alternative financial services. Post-acquisition, Inspira plans to enhance operational efficiencies through the implementation of proprietary technology while leveraging management’s financial technology (FinTech) and operations expertise, in an effort to significantly increase its RLOC and loan book and reduce client acquisition costs.

Inspira’s long-term strategy includes originating patient consumer financing solutions, a potential trillion-dollar market that is virtually untouched by today’s lending industry. From a patient’s perspective, recent changes to the United States healthcare system, including the Affordable Care Act, has resulted in a triple digit increase in the out of pocket patient portion of medical procedures and services, putting enormous pressure on the patient’s ability to pay and the healthcare provider’s ability to collect. Inspira plans to leverage the relationships it gains with the healthcare provider via its RLOC and loan services; combined with proprietary technology built to perfect its security interests can create a distinct advantage to market alternative financial services directly to patients on a very targeted basis.

The Qualifying Transaction

Pursuant to the Qualifying Transaction:

- Chrysalis IX has consolidated its 10,841,000 common shares, on a one for 1.765 basis, into 6,142,209 common shares
- Inspira and a wholly owned subsidiary of Chrysalis IX have amalgamated (“**Amalco**”)
- Chrysalis IX has issued 313,911,540 common shares to Inspira shareholders
- Chrysalis IX has continued into British Columbia and amalgamated with Amalco
- Conditional on receiving final TSX Venture Exchange (the “**TSXV**”) approval, it is anticipated that the common shares of the Resulting Issuer will commence trading under the name Inspira Financial Inc. and symbol LND on July 14, 2015
- the Resulting Issuer will be a Tier I issuer on the TSXV

Additional information relating to Chrysalis IX, Inspira, the Qualifying Transaction, and the Resulting Issuer, including details of the transaction, the new management, board of directors and year end, is available on SEDAR (www.sedar.com).

Pro Forma Capitalization

Following the completion of the Qualifying Transaction, 320,053,750 common shares of the Resulting Issuer are outstanding and 232,811,133 common shares are reserved for issuance. The former Inspira shareholders (including Inspira subscription receipt holders (6.8%) and purchasers under the Inspira concurrent financing (26.7%)) hold approximately 98.1% of the common shares of the Resulting Issuer, and the former Chrysalis IX shareholders hold approximately 1.9% of the common shares of the Resulting Issuer. At the closing of the Qualifying Transaction, 76,150,889 common shares are subject to escrow (with 25% released upon the issuance of the Final Exchange Bulletin) and 33,537,524 are subject to a four month hold with 20% released each month, with the first release upon closing (July 7, 2015).

For more information please contact:

Marc Lavine
Chrysalis Capital IX Corporation
Tel: 1 (877) 272-4073 ext. 2

Dennis Wilson
Inspira Financial Inc.
Tel: 1 (844) 877-7562

This news release contains forward-looking statements regarding the proposed Qualifying Transaction and the business of Inspira. The forward-looking statements contained in this news release represent Chrysalis IX's views and expectations as of the date of this news release and should not be relied upon as representing its views and expectations at any subsequent date. Actual developments may differ materially from those contemplated by these forward-looking statements. The forward-looking events and circumstances discussed in this news release, including the completion and approval of the proposed Qualifying Transaction by the TSXV, the anticipated trading date of the shares of the Resulting Issuer, the size of the potential loan book of Inspira and the future business prospects of Inspira, may not occur or could differ materially as a result of known and unknown risk factors and uncertainties affecting Chrysalis IX and/or Inspira, including (without limitation) risks regarding market conditions, economic factors, and the equity markets generally. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and, except as required by applicable securities laws, Chrysalis IX undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Completion of the proposed transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

The TSXV has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.